Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reissued by equities research analysts at Deutsche Bank AG in a note issued to investors on Monday. They presently have a $65.00 price target on the stock, up from their previous price target of $62.00. Deutsche Bank AG’s price target would suggest a potential upside of 3.06% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Cowen and Company reissued a “buy” rating and issued a $70.00 price target on shares of Zoetis in a research note on Monday. BMO Capital Markets downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $64.00 to $65.00 in a research note on Tuesday, June 13th. They noted that the move was a valuation call. Jefferies Group LLC increased their price target on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. CL King began coverage on shares of Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 price target for the company. Finally, Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $63.11.

Zoetis (NYSE:ZTS) traded down 0.44% on Monday, hitting $63.07. The stock had a trading volume of 1,695,813 shares. The company has a market cap of $30.95 billion, a P/E ratio of 36.67 and a beta of 1.03. The stock’s 50-day moving average is $62.00 and its 200-day moving average is $56.13. Zoetis has a 52-week low of $46.86 and a 52-week high of $63.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 4th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.05. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The company had revenue of $1.23 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the firm earned $0.48 earnings per share. Zoetis’s revenue was up 5.9% on a year-over-year basis. Analysts expect that Zoetis will post $2.33 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/17/zoetis-inc-zts-price-target-increased-to-65-00-by-analysts-at-deutsche-bank-ag.html.

In other news, insider Catherine A. Knupp sold 5,785 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total transaction of $348,025.60. Following the sale, the insider now owns 24,415 shares in the company, valued at $1,468,806.40. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.31% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the stock. New England Research & Management Inc. boosted its stake in Zoetis by 56.1% in the first quarter. New England Research & Management Inc. now owns 29,268 shares of the company’s stock worth $1,562,000 after buying an additional 10,523 shares during the last quarter. Fulton Bank N.A. boosted its stake in Zoetis by 35.8% in the first quarter. Fulton Bank N.A. now owns 5,554 shares of the company’s stock worth $296,000 after buying an additional 1,463 shares during the last quarter. CENTRAL TRUST Co boosted its stake in Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock worth $142,000 after buying an additional 49 shares during the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in Zoetis by 2.6% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 426,303 shares of the company’s stock worth $22,751,000 after buying an additional 10,744 shares during the last quarter. Finally, Atalanta Sosnoff Capital LLC boosted its stake in Zoetis by 39.1% in the first quarter. Atalanta Sosnoff Capital LLC now owns 778,212 shares of the company’s stock worth $41,533,000 after buying an additional 218,905 shares during the last quarter. Hedge funds and other institutional investors own 95.10% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.